



Tulisokibart (MK-7240) Clinical Trials Program

Tulisokibart is an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A).

MSD is developing tulisokibart for the treatment of ulcerative colitis (UC), Crohn's disease (CD), hidradenitis suppurativa (HS), radiographic axial spondyloarthritis (r-axSpA), rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Pivotal Phase 3 Clinical Trials

MSD is conducting multiple pivotal Phase 3 clinical trials to evaluate the efficacy and safety of tulisokibart in patients with the two main types of inflammatory bowel disease (IBD), UC and CD.

Study Titles	Study Name
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants With Moderately to Severely Active Ulcerative Colitis	ATLAS-UC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderately to Severely Active Crohn's Disease	ARES-CD

In addition, there is an ongoing Phase 3 extension study, MK-7240-011, to evaluate the long-term efficacy and safety of tulisokibart in patients who participated in a previous tulisokibart study for UC or CD.

Phase 2 Clinical Trials

MSD is also conducting Phase 2 clinical trials to evaluate the efficacy and safety of tulisokibart in patients with immune-mediated inflammatory diseases in rheumatology and dermatology, including HS, r-axSpA, RA and PsA.

Study Titles	Study Name
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderate to Severe Hidradenitis Suppurativa	MK-7240-012
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis	MK-7240-013
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Rheumatoid Arthritis	MK-7240-014
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis	MK-7240-015